All In Biotech

Drugs by condition

Drugs approved for brain tumors (glioma)

Brand-name prescription drugs and biologics whose FDA label lists brain tumors (glioma) as an approved use. Matched on the label phrases: "glioma", "glioblastoma".

Last checked: Nov 20, 2026Source: FDA labels (openFDA), Drugs@FDAMethods & limitations

Brand-name drugs approved

18

Still marketed, NDA or BLA

Drug classes

5

Novel drugs

8

New molecular entities and new biologics

In development

40+

Investigational drugs in Phase 2 or 3

Newest approvals

The most recently first-approved brand-name drugs for brain tumors (glioma).

  • Pixclara (Floretyrosine F-18) · Telix NovelPriority reviewOrphanSep 11, 2026
  • Modeyso (Dordaviprone Hydrochloride) · Chimerix NovelAccelerated approvalPriority reviewOrphanAug 6, 2025
  • Jobevne (Bevacizumab-Nwgd) · Biocon Biologics INC Apr 9, 2025
  • Ojemda (Tovorafenib) · Day One Biopharms NovelAccelerated approvalPriority reviewOrphanApr 23, 2024
  • Ojemda (Tovorafenib) · Day One Biopharms NovelAccelerated approvalPriority reviewOrphanApr 23, 2024

All approved drugs for brain tumors (glioma), by class

Every marketed NDA or BLA whose current FDA label names this condition in its Indications and Usage section, plus 16 generic labels. A drug can be approved for only part of a condition (one subtype or stage, or as add-on therapy), so check its label.

Vascular Endothelial Growth Factor Inhibitor (6)

  • Avastin Bevacizumab · Genentech · 2004
  • Jobevne Bevacizumab-Nwgd · Biocon Biologics INC · 2025
  • Vegzelma Bevacizumab-Adcd · Celltrion · 2022
  • Alymsys Bevacizumab-Maly · Amneal Pharms LLC · 2022
  • Zirabev Bevacizumab-Bvzr · Pfizer INC · 2019
  • Mvasi Bevacizumab-Awwb · Amgen INC · 2017

Kinase Inhibitor (2)

  • Ojemda Tovorafenib · Day One Biopharms · 2024
  • Ojemda Tovorafenib · Day One Biopharms · 2024

Alkylating Drug (2)

  • Temodar Temozolomide · Merck Sharp Dohme · 2009
  • Gliadel Carmustine · Azurity · 1996

Protease Activator (1)

  • Modeyso Dordaviprone Hydrochloride · Chimerix · 2025

Class not listed in FDA's data (7)

  • Pixclara Floretyrosine F-18 · Telix · 2026
  • Tafinlar Dabrafenib Mesylate · Novartis · 2013
  • Mekinist Trametinib Dimethyl Sulfoxide · Novartis · 2013
  • Bicnu Carmustine · Avet Lifesciences · 1977
  • Mekinist Trametinib, Trametinib Dimethyl Sulfoxide · Novartis · 2023
  • Tafinlar Dabrafenib Mesylate · Novartis · 2023
  • Gleolan Aminolevulinic Acid Hydrochloride · Nxdc · 2017

Drugs in development for brain tumors (glioma)

Investigational drugs FDA has not approved, in active or recent industry-sponsored Phase 2 and 3 trials for this condition. Phase 3 first.

Search the pipeline
  • Anlotinib hydrochlorideAL3818, CatequentenibPhase 312 trials

    Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Alveolar Soft Part Sarcoma, Metastatic Colorectal Cancer, Endometrial Neoplasms

  • L19TNFL19IL2, OnfekafuspPhase 310 trials

    Philogen S.p.A. · Glioblastoma, Locally Advanced Basal Cell Carcinoma, Melanoma Stage III

  • VebreltinibPLB1001Phase 36 trials

    Avistone Biotechnology Co., Ltd. · Non-Small-Cell Lung Cancer, Glioblastoma, Non-Small Cell Lung Cancer

  • luvometinibFCN-159Phase 34 trials

    Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. · Non-small Cell Lung Caner, KRAS-mutated, Metastasis

  • SafusidenibDS-1001b, AB-218Phase 34 trials

    Nuvation Bio Inc. · Oligodendroglioma, Glioma, IDH1-mutant Glioma

  • APG-157Phase 33 trials

    Aveta Biomics, Inc. · Head and Neck Cancer, Squamous Cell Carcinoma of Oral Cavity, Squamous Cell Carcinoma of the Oropharynx

  • pegargiminaseADI-PEG 20Phase 33 trials

    Polaris Group · Glioblastoma Multiforme (GBM), Hepatocellular Carcinoma, Advanced Hepatocellular Carcinoma

  • VRT106Phase 33 trials

    Guangzhou Virotech Pharmaceutical Co., Ltd. · Diffuse Midline Glioma, H3 K27M-Mutant, Diffuse Intrinsic Pontine Glioma, HCC

  • CobolimabPhase 32 trials

    GSK · Melanoma, Hodgkin Lymphoma, High and Low Grade Glioma

  • JK-1201IPhase 32 trials

    JenKem Technology Co., Ltd. · Glioblastoma Multiforme (GBM), Small Cell Lung Cancer

  • LAM561Phase 32 trials

    Laminar Pharmaceuticals · Primary Glioblastoma, Glioblastoma Multiforme, High-grade Glioma

  • INO-9012Phase 24 trials

    Geneos Therapeutics · HCC, Glioblastoma, Urothelial Carcinoma

  • AL58805Phase 22 trials

    Advenchen Pharmaceuticals, LLC. · Endometrial Neoplasms, Soft Tissue Sarcoma (STS), Breast Neoplasms

  • AzeliragonPhase 22 trials

    Cantex Pharmaceuticals · Glioblastoma

  • BreakVaxPhase 22 trials

    BreakBio Corp · Triple-Negative Breast Cancer (TNBC), Glioblastoma (GBM)

  • DOC1021Phase 22 trials

    Diakonos Oncology Corporation · Glioblastoma (GBM), Refractory Melanoma

  • Fianlimab [Fixed ]Phase 22 trials

    Regeneron · Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer

  • INO-5401Phase 22 trials

    Inovio Pharmaceuticals · Glioblastoma, Urothelial Carcinoma

  • T-MAXIMUM Pharmaceutical Inc · Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype, Brain Metastases From Solid Tumors

  • MT-125Phase 22 trials

    Myosin Therapeutics Inc. · Glioblastoma (GBM), Glioblastoma

1 discontinued brand-name drugs whose label still names it

More on brain tumors (glioma): recruiting trials · published research

Related in oncology: Breast cancer · Non-small cell lung cancer · Small cell lung cancer · Prostate cancer · Colorectal cancer · Melanoma · Ovarian cancer · Pancreatic cancer · Bladder and urothelial cancer · Kidney cancer (renal cell carcinoma)

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.